Patents by Inventor Glen Ian ANDREWS

Glen Ian ANDREWS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER
    Publication number: 20220220205
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: February 9, 2022
    Publication date: July 14, 2022
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • Dosing regimen of avelumab for the treatment of cancer
    Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • PD-L1 ANTAGONIST COMBINATION TREATMENTS
    Publication number: 20210069326
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • PD-L1 antagonist combination treatments
    Patent number: 10869924
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 22, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, Adrian Woolfson
  • Dosing Regimen of Avelumab for the Treatment of Cancer
    Publication number: 20190330352
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: October 5, 2017
    Publication date: October 31, 2019
    Applicants: PFIZER INC, MERCK PATENT GmbH
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • PD-L1 Antagonist Combination Treatments
    Publication number: 20180169232
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON